|
Bernd Giebel PhD
Professor
University Duisburg-Essen
Germany
|
Bernd Giebel studied biology in Cologne and received his PhD in 1996. 1999 he moved to the Heinrich-Heine-University of Düsseldorf, to work with human hematopoietic stem and progenitor cells. In 2008 he switched to the University Hospital Essen, continued his studies on human somatic stem cells and started to work with EVs in 2009. Setting a focus on mesenchymal stem/stromal cell-derived EVs (MSC-EVs), together with collaboration partners his group demonstrated the therapeutic potential of MSC-EVs in a human GvHD-patient and in different animal models. It is his goal to efficiently translate MSC-EVs into the clinics and to set up appropriate quality control platforms. BG is the president of the German Society of Extracellular Vesicles (GSEV), co-chairing the exosome working group of the International Society of Gene and Cell Therapy (ISCT) and part of the scientific advisory board of two SME companies, Innovex Therapeutics and Mursla LTD. Furthermore, he is a consultant of FUJIFILM Wako Chemicals Europe GmbH and founding director of Exosla LTD.